|  | Cancer | Cancer Treatment

Paclitaxel (Taxol): Mechanism of Action, Resistance, and Clinical Toxicities

Overview

Paclitaxel (brand name Taxol) is a taxane chemotherapeutic agent derived from Pacific yew bark (Taxus brevifolia). It treats breast, ovarian, non-small cell lung, Kaposi sarcoma, and other cancers.

Primary Mechanism: Microtubule Stabilization

  1. Binding: Paclitaxel binds the β-tubulin subunit of microtubules at the taxane site (distinct from vinca alkaloid site)
  2. Stabilization: Suppresses dynamic instability—promotes polymerization, inhibits depolymerization
  3. Mitotic arrest: Stabilized microtubules prevent spindle disassembly → cells arrest in metaphase (M-phase checkpoint activation)
  4. Apoptosis induction: Prolonged mitotic arrest → intrinsic apoptotic pathway (Bcl-2 phosphorylation, caspase activation, cytochrome c release)

Additional Mechanisms

  • Anti-angiogenesis: Low-dose (metronomic) paclitaxel inhibits endothelial cell migration, tube formation, VEGF signaling
  • Immunomodulation: Enhances dendritic cell maturation, cross-presentation; activates TLR4 on immune cells; may promote immunogenic cell death
  • Non-mitotic effects: Interferes with microtubule-dependent transport, signaling (e.g., HER2 trafficking), and cellular architecture

Pharmacokinetics and Dosing

  • IV infusion (3-hour standard; weekly 1-hour schedules also used)
  • Cremophor EL vehicle → hypersensitivity risk → premedication (dexamethasone, H1/H2 blockers)
  • Albumin-bound formulation (nab-paclitaxel/Abraxane): no Cremophor, shorter infusion, different toxicity profile
  • Hepatic metabolism (CYP2C8, CYP3A4); dose reduce in hepatic impairment

Key Toxicities

ToxicityIncidenceManagement
Peripheral neuropathyDose-limiting; ~60% any gradeDose reduction, schedule change, duloxetine for established neuropathy
NeutropeniaCommon (nadir day 7–10)G-CSF support; dose delay/reduction
HypersensitivityWith Cremophor; rare with nab-paclitaxelPremedication; slow infusion
Arthralgia/myalgia~30% (days 2–5 post-infusion)NSAIDs, gabapentin
Alopecia>80%Scalp cooling may reduce

Resistance Mechanisms

  • β-tubulin mutations (altered binding)
  • Efflux pumps (ABCB1/MDR1, ABCC1/MRP1)
  • Altered microtubule dynamics (τ protein, MAPs)
  • Apoptotic pathway defects (Bcl-2 overexpression, p53 loss)

Paclitaxel exemplifies microtubule-targeted therapy: converting a dynamic cytoskeleton into a lethal trap for dividing cells.

Cancer Treatment - Related Articles